Roberto Speck

SIX SIS Ltd. operates as the national central securities depository of the Swiss financial market and an international central securities depository. It offers services for the settlement and custody of national and international securities. The firm also operates an online real-time settlement system, which enables market participants to settle their transactions through a single technical interface. The company was founded on May 21, 1999 and is headquartered in Olten, Switzerland.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Raiffeisenbank Aschaffenburg eG operates as a state chartered commercial bank. The private company is based in Aschaffenburg, Germany. and has subsidiaries in Germany. The German company was founded in 1878. The CEO is Claus Jäger.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

BioWin ASBL operates as non-profit organization, with interest in the health biotechnology sector. With its member, the firm provides support for the funding in the research and development of biomarkers, nano medicine, drug delivery system, novel therapies, medical devices, and information technology applied to human health. The company is headquartered in Gosselies, Belgium.

Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023.